We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
32.00 | 1.91% | 1,705.00 | 1,701.00 | 1,701.50 | 1,718.50 | 1,673.00 | 1,685.50 | 5,853,296 | 16:35:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.21 | 70.03B |
TIDMAG99 TIDMGSK
RNS Number : 9235Y
GlaxoSmithKline Capital PLC
09 September 2022
Issued: 9 September 2022, London UK
GlaxoSmithKline Capital plc Publication of Base Prospectus
GlaxoSmithKline Capital plc today announced that the following base prospectus dated 7 September 2022 has been approved by the Financial Conduct Authority and is available for viewing:
GSK plc, GlaxoSmithKline Capital plc, GSK Capital BV and GSK Capital KK GBP20,000,000,000 Euro Medium Term Note Programme
Copies of the base prospectus and the documents incorporated by reference within it have been submitted to the UK Listing Authority's National Storage Mechanism (NSM) submission portal via the Electronic Submission System (ESS). The base prospectus will shortly be available for inspection at and can be downloaded from:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
For further information, please contact:
Company Secretary
GSK plc
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom
company.secretary@gsk.com
Enquiries:
UK Media enquiries: Tim Foley +44 (0) 20 8047 (London) 5502 European Analyst/Investor Nick Stone +44 7717 618 834 (London) enquiries: James Dodwell +44 7881 269 066 (London)
BASIS ON WHICH YOU MAY ACCESS THE BASE PROSPECTUS
Please note that the information contained in the base prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the base prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the base prospectus is not addressed. Prior to relying on the information contained in the base prospectus you must ascertain from the base p rospectus whether or not you are part of the intended addressees of the information contained therein.
Your right to access this service is conditional upon complying with the above requirements.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com/company
Registered in England & Wales:
No. 2258699
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
PDIEAPNNEEXAEEA
(END) Dow Jones Newswires
September 09, 2022 04:11 ET (08:11 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions